Health workers’ knowledge on | Treatment policy | Artesunate dose | Artesunate dosing interval | Artesunate preparation | Artesunate route of administration | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | aOR | 95% CI | P-value | |
Age (years) | |||||||||||||||
35–70 | 1.0 (ref) | ||||||||||||||
21–35 | 0.70 | 0.36–1.31 | 0.260 | ||||||||||||
Gender | |||||||||||||||
Female | 1.0 (ref) | 1.0 (ref) | |||||||||||||
Male | 1.02 | 0.63–1.65 | 0.941 | 0.67 | 0.42–1.06 | 0.090 | |||||||||
Cadre | |||||||||||||||
Nurse | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
Clinician | 2.27 | 1.41–3.65 | 0.001 | 2.24 | 1.33–3.77 | 0.002 | 1.76 | 1.15–2.69 | 0.009 | ||||||
Endemicity | |||||||||||||||
Low | 1.0 (ref) | ||||||||||||||
High | 5.79 | 1.17–28.67 | 0.031 | ||||||||||||
CM guidelines | |||||||||||||||
No | 1.0 (ref) | 1.0 (ref) | |||||||||||||
Yes | 2.41 | 1.48–3.93 | <0.001 | 1.59 | 0.99–2.55 | 0.054 | |||||||||
CM training | |||||||||||||||
No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
Yes | 1.33 | 0.74–2.39 | 0.335 | 1.24 | 0.71–2.16 | 0.457 | 1.82 | 0.99–3.35 | 0.056 | ||||||
Supervision | |||||||||||||||
No | 1.0 (ref) | 1.0 (ref) | |||||||||||||
Yes | 3.37 | 0.94–12.0) | 0.061 | 1.42 | 0.64–3.16 | 0.391 | |||||||||
AS poster | |||||||||||||||
No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | ||||||||||||
Yes | 1.07 | 0.59–1.95 | 0.829 | 2.02 | 0.93–4.37 | 0.074 | 1.49 | 0.86–2.60 | 0.154 | 1.67 | 0.93–2.99 | 0.087 | |||
AS in stock | |||||||||||||||
No | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
Yes | 2.01 | 1.05–3.85 | 0.036 | 2.18 | 1.20–3.94 | 0.010 | 1.61 | 0.88–2.96 | 0.121 | 4.73 | 1.50–14.89 | 0.008 | |||
Survey | |||||||||||||||
Baseline | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | |||||||||||
Follow up | 1.61 | 0.94–2.77 | 0.085 | 1.31 | 0.70–2.45 | 0.392 | 1.09 | 0.66–1.82 | 0.733 | 1.38 | 0.81–2.36 | 0.240 |